{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:41:30Z","timestamp":1776728490479,"version":"3.51.2"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cllc.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:22:26Z","timestamp":1771359746000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study"],"prefix":"10.1016","volume":"27","author":[{"given":"Jyoti D.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0488-9631","authenticated-orcid":false,"given":"Aura Cecilia","family":"Jimenez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friso","family":"Coerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Venerus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Inaam-ul Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommi","family":"Tervonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cllc.2026.02.003_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2026.02.003_bib0002","unstructured":"American Cancer Society. Key statistics for lung cancer. [Cited 10 August 2020]; Available from: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html."},{"key":"10.1016\/j.cllc.2026.02.003_bib0003","unstructured":"American Cancer Society. Lung Cancer Survival Rates. [cited [Cited 10 August 2023; Available from: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0004","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/s41467-024-46284-x","article-title":"Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers","volume":"15","author":"Iyer","year":"2024","journal-title":"Nat Commun"},{"issue":"30","key":"10.1016\/j.cllc.2026.02.003_bib0005","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl_1","key":"10.1016\/j.cllc.2026.02.003_bib0006","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.02.003_bib0007","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/annonc\/mdl377","article-title":"Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan","volume":"18","author":"Ohe","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.02.003_bib0008","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non\u2013small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"25","key":"10.1016\/j.cllc.2026.02.003_bib0010","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.cllc.2026.02.003_bib0011","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung Cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N Eng J Med"},{"issue":"21","key":"10.1016\/j.cllc.2026.02.003_bib0012","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"5676","key":"10.1016\/j.cllc.2026.02.003_bib0013","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.cllc.2026.02.003_bib0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cam4.4918","article-title":"Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors","volume":"12","author":"Shenolikar","year":"2023","journal-title":"Cancer Med"},{"issue":"16_suppl","key":"10.1016\/j.cllc.2026.02.003_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e21088","article-title":"Analysis on real-world chemotherapy outcomes in patients (pts) with tyrosine kinase inhibitor (TKI) resistant advanced EGFR-mutant non\u2013small-cell lung cancer (NSCLC) in the United States","volume":"41","author":"Oksen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.cllc.2026.02.003_bib0017","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.cllc.2026.02.003_bib0018","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2026.02.003_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1217793","article-title":"Perspectives of patients with advanced or metastatic non-small cell lung cancer on symptoms, impacts on daily activities, and thresholds for meaningful change: a qualitative research study","volume":"14","author":"Cardellino","year":"2023","journal-title":"Front Psychol"},{"issue":"2","key":"10.1016\/j.cllc.2026.02.003_bib0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0021","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3182397b3e","article-title":"Quality of life and symptom burden among long-term lung cancer survivors","volume":"7","author":"Yang","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.02.003_bib0022","article-title":"Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): Measurement Properties and Estimated Clinically Meaningful Thresholds From a Phase 3 Study","volume":"3","author":"Williams","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cllc.2011.03.033","article-title":"A brief symptom index for advanced lung cancer","volume":"13","author":"Yount","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.02.003_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.602112","article-title":"What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences","volume":"12","author":"Petrocchi","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11136-021-02882-6","article-title":"How patients being treated for non-small cell lung cancer value treatment benefit despite side effects","volume":"31","author":"Martin","year":"2022","journal-title":"Qual Life Res"},{"issue":"7161","key":"10.1016\/j.cllc.2026.02.003_bib0026","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.317.7161.771","article-title":"Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews","volume":"317","author":"Silvestri","year":"1998","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.cllc.2026.02.003_bib0027","doi-asserted-by":"crossref","first-page":"13637","DOI":"10.1002\/cam4.5975","article-title":"Understanding the patient experience and treatment benefits in patients with non-small-cell lung cancer with brain metastasis","volume":"12","author":"Cella","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.cllc.2026.02.003_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1192770","article-title":"How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action","volume":"14","author":"Janssens","year":"2023","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.cllc.2026.02.003_bib0029","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2215\/CJN.11930720","article-title":"Using Patient Preference Information to Inform Regulatory Decision Making: An Opportunity to Spur Patient-Centered Innovation in Kidney Replacement Therapy Devices","volume":"16","author":"Flythe","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0030","doi-asserted-by":"crossref","DOI":"10.2196\/10178","article-title":"EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study","volume":"21","author":"Hernandez","year":"2019","journal-title":"J Med Internet Res"},{"issue":"4","key":"10.1016\/j.cllc.2026.02.003_bib0031","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.clinthera.2016.03.012","article-title":"Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument","volume":"38","author":"McCarrier","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.cllc.2026.02.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: A systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.cllc.2026.02.003_bib0033","article-title":"Saturation in qualitative research: An evolutionary concept analysis","volume":"6","author":"Rahimi","year":"2024","journal-title":"Int J Nurs Stud Adv"},{"issue":"9","key":"10.1016\/j.cllc.2026.02.003_bib0034","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"10.1016\/j.cllc.2026.02.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2020.101409","article-title":"Sleep disorders and cancer: State of the art and future perspectives","volume":"56","author":"Mogavero","year":"2021","journal-title":"Sleep Med Rev"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0036","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1186\/s12885-023-11392-2","article-title":"Sleep disturbances and the risk of lung cancer: a meta-epidemiological study","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2026.02.003_bib0037","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.breast.2022.07.006","article-title":"Progression-free survival and quality of life in metastatic breast cancer: The patient perspective","volume":"65","author":"Mertz","year":"2022","journal-title":"The Breast"},{"issue":"7","key":"10.1016\/j.cllc.2026.02.003_bib0038","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pon.5054","article-title":"Quality of life versus length of life considerations in cancer patients: a systematic literature review","volume":"28","author":"Shrestha","year":"2019","journal-title":"Psychooncology"},{"issue":"12","key":"10.1016\/j.cllc.2026.02.003_bib0039","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jval.2023.08.009","article-title":"A Longitudinal Evaluation of the Preferences of Patients With Advanced Cancer for Quality of Life and Survival in Malaysia: A Discrete Choice Experiment","volume":"26","author":"Yong","year":"2023","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.cllc.2026.02.003_bib0040","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/jnci\/djad138","article-title":"Patients\u2019 attitudes and preferences toward delayed disease progression in the absence of improved survival","volume":"115","author":"Brundage","year":"2023","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0041","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s12888-024-06201-4","article-title":"The relationship between uncertainty and fear of disease progression among newly diagnosed cancer patients: the mediating role of intolerance of uncertainty","volume":"24","author":"Shen","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.cllc.2026.02.003_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2021.100301","article-title":"Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment","volume":"30","author":"Robinson","year":"2021","journal-title":"J Cancer Policy"},{"issue":"12","key":"10.1016\/j.cllc.2026.02.003_bib0043","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.cllc.2026.02.003_bib0044","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/03007995.2021.1888707","article-title":"Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment","volume":"37","author":"Janse","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lungcan.2012.01.016","article-title":"Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis","volume":"77","author":"Bridges","year":"2012","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2026.02.003_bib0046","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10198-014-0622-4","article-title":"Patients' preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer","volume":"16","author":"Muhlbacher","year":"2015","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.cllc.2026.02.003_bib0047","first-page":"149","article-title":"Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer","volume":"3","author":"Dubey","year":"2005","journal-title":"J Support Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0048","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/08943184211051350","article-title":"Best Available Evidence or Truth for the Moment: Bias in Research","volume":"35","author":"Florczak","year":"2021","journal-title":"Nurs Sci Q"},{"key":"10.1016\/j.cllc.2026.02.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: A systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"issue":"1","key":"10.1016\/j.cllc.2026.02.003_bib0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11136-021-02882-6","article-title":"How patients being treated for non-small cell lung cancer value treatment benefit despite side effects","volume":"31","author":"Martin","year":"2022","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.cllc.2026.02.003_bib0051","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/abm\/kaz063","article-title":"Lung Cancer Stigma: Does Smoking History Matter?","volume":"54","author":"Williamson","year":"2020","journal-title":"Ann Behav Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:06:01Z","timestamp":1776726361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1525730426000288"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.02.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}